AstraZeneca Gets a Chance to Prove Its Worth to Pfizer

A positive result at an FDA advisory committee for AstraZeneca's olaparib, which will compete with AbbVie's veliparib, could make the British company more attractive to Pfizer.

Jun 24, 2014 at 2:09PM

A company that rejects a buyout proposal with a 45% stock-price premium had better deliver on its case for being worth more than the offer.

AstraZeneca (NYSE:AZN) gets an early shot to prove its worth tomorrow when a Food and Drug Administration's advisory committee reviews its ovarian cancer drug olaparib. The British drugmaker cited the drug's potential as one reason why Pfizer's (NYSE:PFE) recent acquisition bids were too low.

Good data, but...
The olaparib data look good. Really good. The median progression-free survival for patients with tumors that have BRCA mutations was 11.2 months for those taking olaparib, compared to 4.1 months for the placebo arm. There's an 83% reduction in the risk of progression or death compared to placebo.Pfsolaparib

Source: FDA.

But as with most things is drug development, there's more than meets the eye.

The BRCA group was just a subset of the patients enrolled in the trial. The subgroup was pre-specified, so it's not like AstraZeneca data-mined to find it, but dividing the enrollment means the best data comes from just 96 patients. The FDA is worried that the small size might overemphasize the true magnitude of the effect, especially since the control arm fared worse than one might expect. There's also no statistically significant benefit to overall survival, which is obviously much more important than when the disease progresses, but the lack of statistical significance isn't too surprising given the small sample size.

Side effects
The FDA is quite lenient when it comes to side effects for oncology drugs, considering that most people would rather live longer with these health impacts than die. Serious adverse events occurred in 18.4% of patients taking olaparib, compared to 10.2% of patients in the placebo group, which doesn't look too bad.

The one concern comes from three patients (2.2% of those taking olaparib) who appear to have gotten myelodysplastic syndrome or acute myeloid leukemia. If you combine all the trials to date, AstraZeneca said the rate of patients getting the blood cancers is just 0.8% of those taking olaparib, but the FDA is worried the incidence might be underreported if patients developed the secondary cancer after the study ended.

Good news tomorrow?
I think the advisory panel will recommend the FDA approve olaparib tomorrow. The data in the subgroup is so strong that the outside advisers won't be too worried about the side effects. And AstraZeneca is looking for an accelerated approval, so it'll be conditional on the drug passing on ongoing phase 3 trial anyway. The drug won't be on the market for too long before we figure out if there's an issue with the small sample size skewing the data.

The FDA may not see it that way. The agency, which has the final say, tends to be a little more conservative than its advisers. The flip side to "it won't be too long before we figure out if there's an issue" is "why not just wait for the phase 3 trial."

In the long run, an accelerated approval isn't that important for AstraZeneca sales. Either way, the phase 3 trial needs to be successful for the drug to reach and stay on the market; sales in the interim will be minimal compared to total sales over the life of the drug.

The biggest advantage to an accelerated approval is staying ahead of AbbVie (NYSE:ABBV), which has a drug, veliparib, in the same class. AbbVie posted promising phase 2 data in BRCA ovarian cancer patients with a progression-free survival of 8.1 months. While that doesn't look quite as good as olaparib, the veliparib trial did not feature a control group, so it's hard to compare the data. AbbVie appears to be going after breast cancer first, having started a phase 3 trial in breast cancer patients earlier this year, but it seems likely the two -- or perhaps AbbVie and Pfizer? -- will eventually compete for patients in ovarian and/or breast cancer, assuming both drugs are approved.

The first step is getting past the FDA advisory committee.

Success or not, it won't affect AstraZeneca's dividend
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers